Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 177Neoplasm Metastasis 19Breast Neoplasms 19Prostatic Neoplasms, Castration-Resistant 17Neoplasms 17Metastatic Castration Resistant Prostate Cancer 8Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Triple Negative Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Castration-resistant Prostate Cancer 4Carcinoma, Hepatocellular 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Prostate Adenocarcinoma 3Ovarian Neoplasms 3Carcinoma, Renal Cell 3mCRPC 2Uterine Cervical Neoplasms 2Recurrence 2Prostatic Diseases 2Metastatic Hormone Sensitive Prostate Cancer 2

Interventions

pembrolizumab 3enzalutamide 2blinatumomab 2abiraterone 2Stents 2Neoadjuvant Therapy 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2soybean oil, phospholipid emulsion 1durvalumab 1dostarlimab 1cemiplimab 1camrelizumab 1atezolizumab 1Surgical Procedures, Operative 1Surgical Instruments 1Radiotherapy, Conformal 1Radiotherapy 1Passive Cutaneous Anaphylaxis 1Palliative Care 1Nephrotomy 1Nephrostomy, Percutaneous 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Morphine 1Lidocaine 1Levobupivacaine 1Immunotherapy 1Hydroxyurea 1Etoposide 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Bites and Stings × enzalutamide × Clear all
NCT04221542 2026-05-29

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Amgen

Phase 1 Recruiting
479 enrolled
Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Amgen

Phase 1/2 Terminated
65 enrolled

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon âš¡